Evaluation of Diagnostic Accuracy, Safety, and Cost-Effectiveness of the Non-Invasive Cardiolens FFR-CT Pro Method to Measure the Fractional Flow Reserve in Diagnostics of Chronic Coronary Syndromes Versus the Standard Diagnostic Modalities.
NCT ID: NCT04777513
Last Updated: 2024-05-16
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
450 participants
Study Classification
OBSERVATIONAL
Study Start Date
2020-08-06
Study Completion Date
2023-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A multicentre, post-marketing, observational trial in 450 patients, whose standard diagnostic workup for chronic coronary syndromes provided for Invasive Coronary Angiography (ICA). Medical records of a potential subject of the trial before their enrolment contain a good quality result of at least 128-slice CCTA performed up to 3 months before the elective ICA. CCTA should find at least one ≥50% stenosis in at least one big coronary artery of ≥ 2 mm diameter. At one hour before ICA in the latest the patient should have a resting Continuous Non-Invasive Blood Pressure (CNBP) taken with a certified device delivered by LifeFlow. The last criterion before including a patient in the final analysis is at least one significant (≥50%) stenosis in one or two coronary arteries of ≥ 2 mm diameter visually confirmed by ICA with a FFR measurement taken in these arteries.
The data collection period will cover time from admission for the elective ICA to discharge from the hospital (evaluation of possible adverse events related to invasive procedures).
After initial qualification of available data by the attending physician, selected patients will be asked for a consent to participation in the trial no later than upon admission for the elective ICA and before CNBP measurement.
The data collection period will cover time from admission for the elective ICA to discharge from the hospital (evaluation of possible adverse events related to invasive procedures).
After initial qualification of available data by the attending physician, selected patients will be asked for a consent to participation in the trial no later than upon admission for the elective ICA and before CNBP measurement.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Devices Evaluating Fractional Flow Reserve in Coronary Arteries
NCT03052803
Coronary Artery Disease
Coronary Stenosis
Myocardial Ischemia
COMPLETED
Determination of Fractional Flow Reserve by Anatomic Computed Tomographic Angiography
NCT01233518
Coronary Artery Disease
COMPLETED
NA
Fractional Flow Reserve Versus Angiographically Guided Management to Optimise Outcomes in Unstable Coronary Syndromes
NCT01764334
NonST Elevation Myocardial Infarction
Myocardial Infarction
UNKNOWN
PHASE4
Assessing the Efficacy of CARDIOgoniometry (CGM) to Determine Physiologically Significant Stenosis in Patients With Stable Coronary Artery Disease in Comparison to Fractional FLOW Reserve - CARDIOFLOW
NCT02815631
Coronary Artery Disease
COMPLETED
NA
Correlation of FFR CT With Invasive FFR in Multi-ethnic Cohort- a Retrospective Study
NCT06790836
Coronary Artery Disease
NOT_YET_RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Stage 1
After a patient declares their consent, a doctor or another member of the study team trained by the sponsor will perform procedures in the following order:
* Define the unique patient ID to be recorded in the CRF with the patient's demographic data
* Assess the quality of CCTA imaging data (DICOM) according to guidelines agreed upon with the sponsor and record the number and location of the significant (≥50%) stenosis sites in the CRF based on CCTA
* No later than one hour before ICA starts, perform a physical examination consisting in instantaneous peripheral blood pressure (systolic and diastolic) resting measurement performed with a standard sphygmomanometer and Continuous Non-Invasive Blood Pressure measurement (1-3 min).
Stage 2
After the procedures mentioned above are performed, the patient will undergo elective ICA with the outcomes, i.e.:
* video material showing the location of the wire during the FFR measurement,
* digital pressure signals exported from the FFR measuring device used to determine the value of the invasive FFR,
* values of FFR measurements obtained during ICA will be entered after being anonymised in a dedicated HEMOFLOW PMS\_2020 reference database.
Stage 3
Within 48 hours of ICA completion a doctor or another member of the study team trained by the sponsor:
* will enter the following data in the Cardiolens FFR-CT Pro system:
1. Patient's data, i.e. patient's ID, gender, height, body mass, exercise tolerability, information on used medications and smoking cigarettes. Optionally, i.e. if upon admission for ICA a blood test was performed as a part of the standard diagnostic workup - haematocrit levels and total protein concentration
2. Files containing CCTA imaging data in the DICOM format.
3. Values of instantaneous peripheral blood pressure (systolic and diastolic) resting measurement performed with a standard sphygmomanometer as well as the digital signal obtained during the CNBP measurement (1-3 min)
* Based on the CCTA description or meta data contained in the imaging data the doctor or another member of the study team will record the following information in the CRF:
1. Radiation dose during CCTA
2. Contrast medium dose during CCTA
* Will enter the following information in the CRF:
1. Radiation dose during the diagnostic part of ICA
2. Contrast medium dose during the diagnostic part of ICA
3. Number and type of adverse events
4. Duration of the diagnostic workup.
Stage 4
Within 7 days of entering all the stage 3 data the investigator (a cardiologist) trained by the sponsor will measure the value of the virtual FFR with the Cardiolens FFR-CT Pro system at locations corresponding to ICA FFR measurements (based on video recording entered in the database during stage 2)
Based on results obtained from the Cardiolens FFR-CT Pro system vs reference data an analysis will be performed on meeting the primary and secondary end points of the trial.
After a patient declares their consent, a doctor or another member of the study team trained by the sponsor will perform procedures in the following order:
* Define the unique patient ID to be recorded in the CRF with the patient's demographic data
* Assess the quality of CCTA imaging data (DICOM) according to guidelines agreed upon with the sponsor and record the number and location of the significant (≥50%) stenosis sites in the CRF based on CCTA
* No later than one hour before ICA starts, perform a physical examination consisting in instantaneous peripheral blood pressure (systolic and diastolic) resting measurement performed with a standard sphygmomanometer and Continuous Non-Invasive Blood Pressure measurement (1-3 min).
Stage 2
After the procedures mentioned above are performed, the patient will undergo elective ICA with the outcomes, i.e.:
* video material showing the location of the wire during the FFR measurement,
* digital pressure signals exported from the FFR measuring device used to determine the value of the invasive FFR,
* values of FFR measurements obtained during ICA will be entered after being anonymised in a dedicated HEMOFLOW PMS\_2020 reference database.
Stage 3
Within 48 hours of ICA completion a doctor or another member of the study team trained by the sponsor:
* will enter the following data in the Cardiolens FFR-CT Pro system:
1. Patient's data, i.e. patient's ID, gender, height, body mass, exercise tolerability, information on used medications and smoking cigarettes. Optionally, i.e. if upon admission for ICA a blood test was performed as a part of the standard diagnostic workup - haematocrit levels and total protein concentration
2. Files containing CCTA imaging data in the DICOM format.
3. Values of instantaneous peripheral blood pressure (systolic and diastolic) resting measurement performed with a standard sphygmomanometer as well as the digital signal obtained during the CNBP measurement (1-3 min)
* Based on the CCTA description or meta data contained in the imaging data the doctor or another member of the study team will record the following information in the CRF:
1. Radiation dose during CCTA
2. Contrast medium dose during CCTA
* Will enter the following information in the CRF:
1. Radiation dose during the diagnostic part of ICA
2. Contrast medium dose during the diagnostic part of ICA
3. Number and type of adverse events
4. Duration of the diagnostic workup.
Stage 4
Within 7 days of entering all the stage 3 data the investigator (a cardiologist) trained by the sponsor will measure the value of the virtual FFR with the Cardiolens FFR-CT Pro system at locations corresponding to ICA FFR measurements (based on video recording entered in the database during stage 2)
Based on results obtained from the Cardiolens FFR-CT Pro system vs reference data an analysis will be performed on meeting the primary and secondary end points of the trial.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Stable Ischemic Heart Disease
Coronary Artery Disease
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
CASE_ONLY
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard of care: FFR, ICA, CCTA
Patients with medical history for ischaemic heart disease will take part in non-invasive determination of haemodynamic parameters in coronary arteries with Cardiolens FFR-CT Pro technology.
CCTA (Coronary Computed Tomography Angiography)
Intervention Type
PROCEDURE
Per the protocol, patients had a coronary computed tomography angiography within standard of care before the enrollment to the study.
ICA (Invasive Coronary Angiography)
Intervention Type
PROCEDURE
Per the protocol, patients will have an Invasive Coronary Angiography within standard of care.
FFR (Fractional Flow Reserve)
Intervention Type
PROCEDURE
Per the protocol, patients will have a Fractional Flow Reserve procedure within standard of care.
CNBP measurement
Intervention Type
DEVICE
Per the protocol, patients will have the measurement of the resting Continuous Non-Invasive Blood Pressure (CNBP). The signal is required for iSIL-FFR technology.
Cardiolens FFR-CT Pro
Intervention Type
DEVICE
Per the protocol, non-invasive FFR measurements will be perfomed via Cardiolens FFR-CT Pro technology for the enrolled patients.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CCTA (Coronary Computed Tomography Angiography)
Per the protocol, patients had a coronary computed tomography angiography within standard of care before the enrollment to the study.
Intervention Type
PROCEDURE
ICA (Invasive Coronary Angiography)
Per the protocol, patients will have an Invasive Coronary Angiography within standard of care.
Intervention Type
PROCEDURE
FFR (Fractional Flow Reserve)
Per the protocol, patients will have a Fractional Flow Reserve procedure within standard of care.
Intervention Type
PROCEDURE
CNBP measurement
Per the protocol, patients will have the measurement of the resting Continuous Non-Invasive Blood Pressure (CNBP). The signal is required for iSIL-FFR technology.
Intervention Type
DEVICE
Cardiolens FFR-CT Pro
Per the protocol, non-invasive FFR measurements will be perfomed via Cardiolens FFR-CT Pro technology for the enrolled patients.
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Age ≥ 18
2. Declaration of informed consent to sharing medical records gathered during the standard diagnostic workup
3. History of chronic coronary syndromes (CCS)
4. Diagnostic CCTA (good quality test allowing investigation of the entire coronary artery tree), showing at least one site with stenosis ≥50% of the lumen in a large coronary artery of ≥ 2 mm diameter, with no prior revascularisation
5. Standard treatment of chronic coronary syndromes with no dosage modification required within at least 4 weeks before the enrolment
6. Patients with a prior acute coronary syndrome (ACS) or revascularisation would be found eligible under the following conditions:
* Over 30 days from the acute coronary syndrome occurrence
* FFR assessment during ICA may only cover the vessels that were not revascularized (both PCI and CABG) and were not the reason of ACS
* No closed coronary arteries
2. Declaration of informed consent to sharing medical records gathered during the standard diagnostic workup
3. History of chronic coronary syndromes (CCS)
4. Diagnostic CCTA (good quality test allowing investigation of the entire coronary artery tree), showing at least one site with stenosis ≥50% of the lumen in a large coronary artery of ≥ 2 mm diameter, with no prior revascularisation
5. Standard treatment of chronic coronary syndromes with no dosage modification required within at least 4 weeks before the enrolment
6. Patients with a prior acute coronary syndrome (ACS) or revascularisation would be found eligible under the following conditions:
* Over 30 days from the acute coronary syndrome occurrence
* FFR assessment during ICA may only cover the vessels that were not revascularized (both PCI and CABG) and were not the reason of ACS
* No closed coronary arteries
Exclusion Criteria
1. CCTA-confirmed myocardial bridges causing \>50% stenosis of the epicardial vascular lumen
2. Coronary obstruction confirmed by CCTA or invasive coronarography
3. History of ACS with coronary angioplasty or Coronary Artery Bypass Grafting (CABG) performed unless point 6 conditions are met
4. Significant haemodynamic abnormalities of the valve or history of surgical correction of the defect or CABG
5. Second-degree or third-degree atrioventricular block, sinus node dysfunction, QTc \> 450 ms or prolonged QTc
6. LVEF ≤ 35% found in an echocardiogram performed within the last 6 months
7. BMI ≥ 35
8. Clinically apparent infection
9. Thrombocytopenia below 100.000/mm3
10. Active neoplastic disease (apart from basal cell carcinoma and carcinoma in situ) and other conditions, which, in the investigator's opinion significantly affect their life expectancy
11. Other significant conditions, infections, addictions and psychological or social factors, which, in the doctor's opinion, may affect patient's ability to participate in the trial or significantly affect their safety
2. Coronary obstruction confirmed by CCTA or invasive coronarography
3. History of ACS with coronary angioplasty or Coronary Artery Bypass Grafting (CABG) performed unless point 6 conditions are met
4. Significant haemodynamic abnormalities of the valve or history of surgical correction of the defect or CABG
5. Second-degree or third-degree atrioventricular block, sinus node dysfunction, QTc \> 450 ms or prolonged QTc
6. LVEF ≤ 35% found in an echocardiogram performed within the last 6 months
7. BMI ≥ 35
8. Clinically apparent infection
9. Thrombocytopenia below 100.000/mm3
10. Active neoplastic disease (apart from basal cell carcinoma and carcinoma in situ) and other conditions, which, in the investigator's opinion significantly affect their life expectancy
11. Other significant conditions, infections, addictions and psychological or social factors, which, in the doctor's opinion, may affect patient's ability to participate in the trial or significantly affect their safety
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GENELYTICA Sp. z o.o.
UNKNOWN
Sponsor Role
collaborator
Hemolens Diagnostics Sp. z o.o.
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cezary Kępka, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
The National Institute of Cardiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
American Heart of Poland, Centrum Kardiologii i Kardiochirurgii w Bielsku-Białej
Bielsko-Biala, , Poland
Site Status
The University Clinical Centre
Gdansk, , Poland
Site Status
The Leszek Giec Upper-Silesian Medical Centre of the Silesian Medical University
Katowice, , Poland
Site Status
Oddział Kliniczny Kardiologii oraz Interwencji Sercowo-Naczyniowych Szpital Uniwersytecki w Krakowie
Krakow, , Poland
Site Status
The John Paul II Specialist Hospital in Cracovia
Krakow, , Poland
Site Status
"Miedziowe Centrum Zdrowia" S.A.
Lubin, , Poland
Site Status
American Heart of Poland, Centrum Sercowo - Naczyniowe w Ustroniu
Ustroń, , Poland
Site Status
The Cardinal Stefan Wyszyński National Institute of Cardiology
Warsaw, , Poland
Site Status
The 4th Military Teaching Hospital
Wroclaw, , Poland
Site Status
The Jan Mikulicz-Radecki University Teaching Hospital
Wroclaw, , Poland
Site Status
The T. Marciniak Lower Silesian Specialist Hospital - Center of Emergency Medicine
Wroclaw, , Poland
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Poland
References
Explore related publications, articles, or registry entries linked to this study.
Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F; European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012 Jul;33(13):1635-701. doi: 10.1093/eurheartj/ehs092. Epub 2012 May 3. No abstract available.
Reference Type
BACKGROUND
Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Uva MS, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A; Grupa Robocza Europejskiego Towarzystwa Kardiologicznego (ESC); Europejskie Stowarzyszenie Chirurgii Serca i Klatki Piersiowej (EACTS) do spraw rewaskularyzacji miesnia sercowego; European Association for Percutaneous Cardiovascular Interventions (EAPCI). [2014 ESC/EACTS Guidelines on myocardial revascularization]. Kardiol Pol. 2014;72(12):1253-379. doi: 10.5603/KP.2014.0224. No abstract available. Polish.
Reference Type
BACKGROUND
Authors/Task Force members; Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014 Oct 1;35(37):2541-619. doi: 10.1093/eurheartj/ehu278. Epub 2014 Aug 29. No abstract available.
Reference Type
BACKGROUND
Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, Klauss V, Manoharan G, Engstrom T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009 Jan 15;360(3):213-24. doi: 10.1056/NEJMoa0807611.
Reference Type
BACKGROUND
Lindstaedt M, Fritz MK, Yazar A, Perrey C, Germing A, Grewe PH, Laczkovics AM, Mugge A, Bojara W. Optimizing revascularization strategies in patients with multivessel coronary disease: impact of intracoronary pressure measurements. J Thorac Cardiovasc Surg. 2005 Apr;129(4):897-903. doi: 10.1016/j.jtcvs.2004.08.036.
Reference Type
BACKGROUND
Reczuch K, Jankowska E, Telichowski A, Porada A, Banasiak W, Ponikowski P. Measurement of fractional flow reserve in patients with multi-vessel coronary artery disease and borderline lesions prevents unnecessary revascularisation procedures. Kardiol Pol. 2004 Apr;60(4):311-19; discussion 320-1. English, Polish.
Reference Type
BACKGROUND
Toth G, De Bruyne B, Casselman F, De Vroey F, Pyxaras S, Di Serafino L, Van Praet F, Van Mieghem C, Stockman B, Wijns W, Degrieck I, Barbato E. Fractional flow reserve-guided versus angiography-guided coronary artery bypass graft surgery. Circulation. 2013 Sep 24;128(13):1405-11. doi: 10.1161/CIRCULATIONAHA.113.002740. Epub 2013 Aug 28.
Reference Type
BACKGROUND
De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, Jagic N, Mobius-Winkler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engstrom T, Oldroyd KG, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Juni P, Fearon WF; FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012 Sep 13;367(11):991-1001. doi: 10.1056/NEJMoa1205361. Epub 2012 Aug 27.
Reference Type
BACKGROUND
De Bruyne B, Pijls NH, Barbato E, Bartunek J, Bech JW, Wijns W, Heyndrickx GR. Intracoronary and intravenous adenosine 5'-triphosphate, adenosine, papaverine, and contrast medium to assess fractional flow reserve in humans. Circulation. 2003 Apr 15;107(14):1877-83. doi: 10.1161/01.CIR.0000061950.24940.88. Epub 2003 Mar 31.
Reference Type
BACKGROUND
Wongpraparut N, Yalamanchili V, Pasnoori V, Satran A, Chandra M, Masden R, Leesar MA. Thirty-month outcome after fractional flow reserve-guided versus conventional multivessel percutaneous coronary intervention. Am J Cardiol. 2005 Oct 1;96(7):877-84. doi: 10.1016/j.amjcard.2005.05.040.
Reference Type
BACKGROUND
Leone AM, Martin-Reyes R, Baptista SB, Amabile N, Raposo L, Franco Pelaez JA, Trani C, Cialdella P, Basile E, Zimbardo G, Burzotta F, Porto I, Aurigemma C, Rebuzzi AG, Faustino M, Niccoli G, Abreu PF, Slama MS, Spagnoli V, Telleria Arrieta M, Amat Santos IJ, de la Torre Hernandez JM, Lopez Palop R, Crea F. The Multi-center Evaluation of the Accuracy of the Contrast MEdium INduced Pd/Pa RaTiO in Predicting FFR (MEMENTO-FFR) Study. EuroIntervention. 2016 Aug 20;12(6):708-15. doi: 10.4244/EIJV12I6A115.
Reference Type
BACKGROUND
Wu W, Pan DR, Foin N, Pang S, Ye P, Holm N, Ren XM, Luo J, Nanjundappa A, Chen SL. Noninvasive fractional flow reserve derived from coronary computed tomography angiography for identification of ischemic lesions: a systematic review and meta-analysis. Sci Rep. 2016 Jul 5;6:29409. doi: 10.1038/srep29409.
Reference Type
BACKGROUND
Nakazato R, Park HB, Berman DS, Gransar H, Koo BK, Erglis A, Lin FY, Dunning AM, Budoff MJ, Malpeso J, Leipsic J, Min JK. Noninvasive fractional flow reserve derived from computed tomography angiography for coronary lesions of intermediate stenosis severity: results from the DeFACTO study. Circ Cardiovasc Imaging. 2013 Nov;6(6):881-9. doi: 10.1161/CIRCIMAGING.113.000297. Epub 2013 Sep 30.
Reference Type
BACKGROUND
Min JK, Leipsic J, Pencina MJ, Berman DS, Koo BK, van Mieghem C, Erglis A, Lin FY, Dunning AM, Apruzzese P, Budoff MJ, Cole JH, Jaffer FA, Leon MB, Malpeso J, Mancini GB, Park SJ, Schwartz RS, Shaw LJ, Mauri L. Diagnostic accuracy of fractional flow reserve from anatomic CT angiography. JAMA. 2012 Sep 26;308(12):1237-45. doi: 10.1001/2012.jama.11274.
Reference Type
BACKGROUND
Morris PD, van de Vosse FN, Lawford PV, Hose DR, Gunn JP. "Virtual" (Computed) Fractional Flow Reserve: Current Challenges and Limitations. JACC Cardiovasc Interv. 2015 Jul;8(8):1009-1017. doi: 10.1016/j.jcin.2015.04.006. Epub 2015 Jun 24.
Reference Type
BACKGROUND
Kruk M, Wardziak L, Demkow M, Pleban W, Pregowski J, Dzielinska Z, Witulski M, Witkowski A, Ruzyllo W, Kepka C. Workstation-Based Calculation of CTA-Based FFR for Intermediate Stenosis. JACC Cardiovasc Imaging. 2016 Jun;9(6):690-9. doi: 10.1016/j.jcmg.2015.09.019. Epub 2016 Feb 17.
Reference Type
BACKGROUND
DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988 Sep;44(3):837-45.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
http://www.who.int/mediacentre/factsheets/fs317/en/
WHO Fact sheet N°317 September 2012
http://who.int/mediacentre/factsheets/fs310/en/
WHO Fact sheet N°310 Updated June 2011
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HEMOFLOW PMS_2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Diagnostic Agreement of iFR and QFR.
NCT03420131
UNKNOWN
Comparison of the Diagnostic Performance and Costs of FFRB Vs. Standard Care in Suspected Coronary Artery Disease.
NCT06681584
ACTIVE_NOT_RECRUITING
One-Dimensional Mathematical Model-Based Automated Assessment of Fractional Flow Reserve
NCT03797118
COMPLETED
NA
In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes?
NCT02892903
UNKNOWN
NA
RFR and FFR for the the Prediction of Post-PCI Results
NCT04417634
UNKNOWN
PHASE4
Comparison of Vessel-FFR Versus FFR in Intermediate Coronary Stenoses
NCT03497637
RECRUITING
NA
Validation of Stenosis Assessment by Coronary Artery Computed Tomography Against Invasive Measurements of Fractional Flow Reserve in Patients With Significant Coronary Artery Stenoses
NCT00817102
COMPLETED
NA
Analysis of Coronary CT Angiography to Identify Patients With Significant Coronary Artery Stenosis
NCT02791113
UNKNOWN
Diagnostic Accuracy of CT-FFR Compared to Invasive Coronar Angiography With Fractional Flow Reserve
NCT03045601
COMPLETED
NA
Fractional Flow Reserve Derived From CT Related Treatment
NCT05319119
UNKNOWN
Effect of FFRCT-angio in Functional Diagnosis of Coronary Artery Stenosis
NCT04493086
UNKNOWN
The Heartflow Coronary Disease Progression Evaluation Study
NCT04052256
UNKNOWN
Angio-based Fractional Flow Reserve to Predict Adverse Events After Stent Implantation
NCT02811796
COMPLETED
Fractional Flow Reserve or 3D-Quantitative-Coronary-Angiography Based Vessel-FFR Guided Revascularization
NCT04931771
UNKNOWN
NA
Validation of a Predictive Model of Coronary Fractional Flow Reserve in Patients With Intermediate Coronary Stenosis
NCT03054324
UNKNOWN
Comparisons of Morphological Measurement Between Coronary Computed Tomography and Optical Coherence Tomography
NCT03021382
COMPLETED
Evaluation of Accuracy of CFD-based RuiXin-FFR by Comparing With Pressure-wire-based FFR
NCT04731285
COMPLETED
Computed Tomography-derived Fractional Flow Reserve vs. Angiographic Quantitative Flow Ratio in Management of Patients With Coronary Artery Disease
NCT07308496
NOT_YET_RECRUITING
NA
Clinical Usefulness of Fractional Flow Reserve Measurement for Significant Stenosis in Proximal Coronary Artery
NCT02475291
COMPLETED
Diagnostic Performance of Fractional Flow Reserve Derived From Coronary CT Angiography
NCT04426396
COMPLETED
"SIMULATION MODELING OF CORONARY ARTERY DISEASE: A TOOL FOR CLINICAL DECISION SUPPORT"
NCT04448691
COMPLETED
NA
Outcomes With Fractional Flow Reserve in Chronic Coronary Syndrome
NCT05592535
COMPLETED
Diagnostic Performance of On-site Automatic Coronary Computed Tomography Angiography-derived Fractional Flow Reserve
NCT06153927
COMPLETED
Follow-up With CT-FFR in CHD Patients After DCB
NCT04664439
UNKNOWN
NA
Coronary Flow and Myocardial Viability: the FloVITA Study
NCT04818918
RECRUITING